Combined Anticancer Treatment of Advanced Colon Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-10-31

Study Completion Date

2017-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The COMBATAC study evaluates the the effect as assessed by progression-free survival (PFS) of perioperative systemic chemotherapy including cetuximab and cytoreductive surgery (CRS) and bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with peritoneal carcinomatosis arising from colorectal cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases

NCT02758951

Colorectal Neoplasm Colorectal Cancer Colorectal Neoplasms Malignant +8 more

ACTIVE_NOT_RECRUITING PHASE2/PHASE3

Adjuvant HIPEC to Prevent Colorectal Peritoneal Metastases in High-risk Patients

NCT02575859

Colorectal Neoplasm Metastasis

COMPLETED PHASE1/PHASE2

Radical Colorectal Resection and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Locally Advanced Colorectal Cancer

NCT02830139

Malignant Neoplasm of Colorectum

COMPLETED PHASE2

An Audit of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy

NCT02754115

Colorectal Cancer Ovarian Cancer Peritoneal Disease

RECRUITING

Clinical Trial to Evaluate Safety and Efficacy of Hyperthermic Intra-peritoneal Chemotherapy (HIPEC) With Mitomycin C Used During Surgery for Treatment of Locally Advanced Colorectal Carcinoma

NCT02614534

Colorectal Cancer

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

More than 10% of patients with colorectal cancer (CRC) already show peritoneal carcinomatosis at the time of initial diagnosis and up to 25% of all patients develop peritoneal carcinomatosis during the natural course of their disease as a common sign of tumor progression or recurrence.

The existing data suggests that CRS and HIPEC as an integral part of a multidisciplinary treatment concept may improve long-term survival of selected patients with peritoneal carcinomatosis of colonic origin. Moreover, hyperthermic peritoneal perfusion with oxaliplatin in combination with synchronous application of 5-FU/leucovorin seems to improve the efficacy of HIPEC in comparison to a mitomycin C-based intraperitoneal treatment regimen and may lead to a better local tumor control. The improved systemic treatment strategy with neoadjuvant chemotherapy may lead to increased rates of complete macroscopic cytoreduction and together with the adjuvant treatment to better control of distant metastasis and tumor recurrence. However, there is no prospective study available evaluating the clinical and oncological outcome after standard-of-care chemotherapy including targeted anticancer therapy in combination with CRS and HIPEC. The published morbidity and mortality rates after CRS and HIPEC are comparable to other major gastrointestinal surgery and seem to be acceptable considering the expected improvement of oncological outcome.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Peritoneal Carcinomatosis Colorectal Cancer Metastatic

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment Arm

1. FOLFOX/FOLFIRI + cetuximab (6 cycles)
2. CRS and HIPEC
3. FOLFOX/FOLFIRI + cetuximab (6 cycles)

Group Type EXPERIMENTAL

CRS

Intervention Type PROCEDURE

complete macroscopic cytoreduction (CC-0/1)

HIPEC

Intervention Type DRUG

bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CRS

complete macroscopic cytoreduction (CC-0/1)

Intervention Type PROCEDURE

HIPEC

bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Cytoreductive surgery Hyperthermic intraperitoneal chemotherapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Synchronous or metachronous peritoneal carcinomatosis arising from histologically proven colorectal or appendiceal adenocarcinoma
* Complete macroscopic cytoreduction (CCR-0/1)
* Free treatment interval of at least 6 month after the last chemotherapy
* Age over 18 and below 71 years
* Good general health status (Karnofsky \> 70%, ECOG 0-2)
* Absence of hematogenous metastasis (lung, bone, brain, \> 3 peripheric resectable liver metastases)
* Absence of contraindication for systemic chemotherapy and/or extended surgery
* Life expectancy greater than 6 months
* Written informed consent
* Creatinine clearance \> 50 ml/min, serum creatinine ≤ 1.5 x ULN
* Serum bilirubin ≤ 1.5 x ULN (upper limit of normal), ASAT and ALAT ≤ 2.5 x ULN
* Platelet count \> 100,000 /ml, haemoglobin \> 9 g/dl, neutrophile granulocytes ≥ 1,500 /ml, International Normalized Ration (INR) ≤ 2
* Absence of peripheral neuropathy \> grade 1 (CTCAE v4.0)
* No pregnancy or breast feeding. Adequate contraception in fertile patients.

* Heart failure NYHA ≥ 2 or significant Coronary Artery Disease
* Alcohol and/or drug abuse
* Patients unable or unwilling to comply with the study protocol, treatment or follow-up
* Patients included in other clinical trials interfering with the present study

Exclusion Criteria

* Incomplete cytoreduction
* Hematogenous metastasis including irresectable liver metastasis
* Prior chemotherapy or therapy with EGFR receptor antibody for metastatic disease
* K-ras mutation
* Known allergy to murine or chimeric monoclonal antibodies
* Histology of signet ring carcinoma
* Other malignancy than disease under study / second cancer

Minimum Eligible Age

18 Years

Maximum Eligible Age

71 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No